PéptidosRD.COM

Single Peptides · Exact presentation

Retatrutide · 10 mg Vial

Retatrutide · 10 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.

Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.

View latest COA
Retatrutide · 10 mg Vial — Nova Labs

Separate commercial record

Availability in the Dominican Republic

This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.

Dosing & Reconstitution Guide

The tables below keep the gradual and advanced approaches separate. Both use the same 10 mg/mL concentration, but their final progression and vial requirements differ.

Standard / Gradual Approach (1 mL = ~10.0 mg/mL)

The gradual approach progresses in four-week blocks: 2 mg, 4 mg, 6 mg, and finally 8 mg weekly. Each row retains the U-100 volume and vial count for the exact 10 mg presentation.

Standard / Gradual Approach (1 mL = ~10.0 mg/mL)

PhaseWeekly DoseUnits (per injection) (mL)Vials Needed
Weeks 1–42 mg (2000 mcg)20 units (0.20 mL)1 vial per dose
Weeks 5–84 mg (4000 mcg)40 units (0.40 mL)1 vial per dose
Weeks 9–126 mg (6000 mcg)60 units (0.60 mL)1 vial per dose
Weeks 13+8 mg (8000 mcg)80 units (0.80 mL)1 vial per dose

Reconstitution Steps

Withdraw 1.0 mL bacteriostatic water with sterile equipment; introduce it slowly down the vial wall; roll gently without shaking; date the vial; refrigerate at 2–8 °C away from light; and use within four weeks.

Advanced / Aggressive Protocol (1 mL = ~10.0 mg/mL)

The advanced approach retains 2 mg and 4 mg during the first eight weeks, moves to 8 mg, and reaches 12 mg from week 13. The 12 mg phase requires two 10 mg vials and 1.20 mL total volume, generally divided between two sites.

Advanced / Aggressive Protocol (1 mL = ~10.0 mg/mL)

PhaseWeekly DoseUnits (per injection) (mL)Vials Needed
Weeks 1–42 mg (2000 mcg)20 units (0.20 mL)1 vial per dose
Weeks 5–84 mg (4000 mcg)40 units (0.40 mL)1 vial per dose
Weeks 9–128 mg (8000 mcg)80 units (0.80 mL)1 vial per dose
Weeks 13+12 mg (12000 mcg)120 units (1.20 mL)2 vials per dose**

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]

Allow vials to reach room temperature before opening to reduce condensation uptake.

How This Works

Retatrutide activates GLP-1, GIP, and glucagon receptors. The two incretin pathways relate to satiety and glucose regulation, while glucagon signaling is studied for energy expenditure. A lipid modification extends exposure and supports weekly evaluation.

Clinical Benefits & Side Effects

Phase 2 studies evaluated weight, glycemic control, and cardiometabolic markers. Nausea, vomiting, and diarrhea were the most frequent adverse effects, particularly during escalation. Controlled-trial results do not validate unverified research products.

Benefits

In participants with obesity without diabetes, 8–12 mg groups reached mean weight reductions near 22–24% at 48 weeks. Type 2 diabetes studies observed HbA1c reductions and cardiometabolic changes; magnitude depended on dose and study.

Source trail

Scientific references and source discovery

How PeptidosRD selects, separates, and reviews sources